Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment crawled date : 2022 - 03 - 09 save search
Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-5001 for the Treatment of Acute Myeloid Leukemia
Published: 2022-03-09 (Crawled : 23:00) - globenewswire.com
NTLA | $21.5 -1.42% -1.35% 830K
|
Health Technology
|
| O: -2.09%
H: 2.75%
C: 2.01%
ntla-5001 treatment fda myeloid leukemia drug leukemia 500 therapeutics drug designation intel orphan drug designation acute myeloid leukemia
C4 Therapeutics Announces FDA Orphan Drug Designation for CFT8634 for the Treatment of Soft Tissue Sarcoma
Published: 2022-03-09 (Crawled : 22:00) - biospace.com/
CCCC | $6.87 0.59% 0.87% 1.4K
|
Health Technology
|
| O: 5.67%
H: 11.76%
C: 9.1%
cft8634 treatment fda drug therapeutics drug designation orphan drug designation soft tissue
Acadia Pharmaceuticals Announces August 4, 2022 Action Date for Resubmitted Supplemental New Drug Application for NUPLAZID® (pimavanserin) for the Treatment of Alzheimer’s Disease Psychosis
Published: 2022-03-09 (Crawled : 21:00) - biospace.com/
ACAD | News | $17.19 0.64% 0.7% 690K
|
Health Technology
|
| O: 2.14%
H: 13.64%
C: 7.87%
nuplazid new drug alzheimer treatment als application drug disease alzheimer’s alzheimer's disease alzheimer's
Compugen Presents New Research Suggesting Targeting DNAM-1 Axis Holds Promise for Treatment of Multiple Myeloma
Published: 2022-03-09 (Crawled : 13:00) - biospace.com/
CGEN | $2.03 3.57% 3.45% 450K
|
Health Technology
|
| O: 6.35%
H: 8.39%
C: 8.06%
treatment research
Pfizer Initiates Phase 2/3 Study of Novel COVID-19 Oral Treatment in Pediatric Participants
Published: 2022-03-09 (Crawled : 13:00) - biospace.com/
PFE A | $25.42 -1.05% 0.16% 40M
|
Health Technology
|
| O: 1.28%
H: 2.26%
C: 1.29%
covid-19 treatment phase 2 phase 2/3 covid
Design Therapeutics Announces Preclinical Data Highlighting Novel GeneTAC™ Therapy for the Treatment of Fuchs Endothelial Corneal Dystrophy to be Presented at ARVO 2022
Published: 2022-03-09 (Crawled : 12:00) - globenewswire.com
DSGN | $3.94 6.78% 6.58% 130
|
Professional, Scientific, and T...
|
| O: 2.53%
H: 12.75%
C: 8.46%
treatment therapeutics preclinical therapy pre-clinical designation
Efanesoctocog alfa met primary and key secondary endpoints in pivotal study in hemophilia A, demonstrating superiority to prior factor prophylaxis treatment
Published: 2022-03-09 (Crawled : 10:00) - biospace.com/
SNYNF | News | $92.7 0.63% -2.18% 1.4K
|
Health Technology
|
| O: -0.5%
H: 0.0%
C: 0.0%
SNY | News | $46.11 0.68% 0.7% 3.5M
|
Health Technology
|
| O: 1.41%
H: 0.0%
C: 0.0%
treatment
Efanesoctocog alfa met primary and key secondary endpoints in pivotal study in haemophilia A, demonstrating superiority to prior factor prophylaxis treatment
Published: 2022-03-09 (Crawled : 07:00) - prnewswire.com
SNYNF | News | $92.7 0.63% -2.18% 1.4K
|
Health Technology
|
| O: -0.5%
H: 0.0%
C: 0.0%
SNY | News | $46.11 0.68% 0.7% 3.5M
|
Health Technology
|
| O: 1.41%
H: 0.0%
C: 0.0%
treatment haemophilia
Sinusitis Treatment Market to Rise at CAGR of 3.6% during Forecast Period, Observes TMR Study
Published: 2022-03-09 (Crawled : 04:00) - prnewswire.com
LLY | News | $750.77 0.54% 0.15% 8.3K
|
Health Technology
|
| O: 1.37%
H: 1.71%
C: -0.19%
treatment
Gainers vs Losers
| 57% | 43% |
Top 10 Gainers
INVO | $1.82 139.47% 49.67% 1.4M
|
Health Technology
WISA 4 | $9.25 51.64% 34.27% 64M
|
Electronic Technology
HOLO | $2.24 -5.49% 27.74% 7.7M
|
SRFM 4 | $0.3859 -12.3% 23.84% 660K
|
n/a
CTM | $0.2201 -2.31% 22.67% 48K
|
n/a
VIAO | $0.262 0.77% 16.03% 14M
|
Electronic Technology
DXF | $0.2708 -5.71% 14.48% 190K
|
Finance
GRFX | $0.2159 -10.04% 12.55% 5.9K
|
n/a
BHIL | $0.1722 -3.8% 12.08% 290K
|
Agriculture, Forestry, Fishing ...
ANVS | $8.99 -10.81% 10.9% 270K
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.